USA — GSK, a British multinational pharmaceutical and biotech company has entered into a three-year partnership with Tempus to expand its access to its AI-powered data library, including de-identified patient data, with a US$70 million initial payment.
GSK claims that the collaboration will allow it to use the library of the US-based company to accelerate drug discovery in oncology, improve clinical trial design, identify drug targets, and accelerate trial enrollment.
GSK has the option to extend the agreement for another two years after three years.
The collaboration expands on GSK and Tempus’ previous collaboration focused on clinical trial enrollment of patients with specific cancer types, allowing GSK to specifically access Tempus’ de-identified patient data.
The companies are currently working together on an open-label phase II study, using a data-driven approach to shorten study timelines.
GSK has collaborated with a number of companies in the last year to strengthen its clinical research functions.
GSK announced a multiyear drug discovery partnership with AI-enabled pathology company PathAI in April of this year to advance clinical trials and drug development in oncology and nonalcoholic steatohepatitis (NASH).
GSK announced earlier this year that it had extended its drug discovery partnership with consumer genetics company 23andMe until July 2023. GSK provided US$300 million to the now publicly traded company in 2018, kicking off the collaboration.
GSK expanded its collaboration with Viome Life Sciences, a maker of at-home tests for gut and immune system health, last year.
The collaboration enables GSK to investigate the relationship between the gut microbiome and certain chronic diseases, such as autoimmune disorders.
In the funding arena, Tempus also raised US$275 million in equity from previous investors and debt financing from Ares Management. According to Crunchbase, the company has raised more than US$1.3 billion.
This is a significant raise, and for good reason: The Tempus technology is aimed at three areas of data-driven care that are currently undergoing the most change: drug discovery, clinical trials, and diagnostics.
Chicago-based Tempus specializes in artificial intelligence and precision medicine for a variety of applications.
Using AI, the platform can assist doctors in understanding disease progression and what causes the disease. It can also help you find the right patients for a clinical trial.
The platform can analyze patient health at the granular level using genomic sequencing, allowing physicians to understand why a patient has a disease.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
